Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck Cancer
Sponsor: Andrei Iagaru
A PHASE1 clinical study on Carcinoma of the Head and Neck and Squamous Cell Carcinoma of the Head and Neck, this trial is completed. The trial is conducted by Andrei Iagaru and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2022 — Jun 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Feb 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Andrei Iagaru
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .